Nautilus Biotechnology Inc.
Classification
Public
About
About
Nautilus Biotechnology, Inc. is a biotechnology company dedicated to revolutionizing the field of life sciences through innovative and advanced technologies. The company is focused on developing transformative tools and solutions that enable researchers, scientists, and clinicians to gain deeper insights into the complexities of biological systems. By leveraging state-of-the-art techniques, Nautilus aims to accelerate scientific discovery, enhance diagnostics, and drive breakthroughs in various areas of biology and medicine. Product/Service Line Breakdown: 1. Omics Platform: Nautilus Biotechnology's flagship product is its highly sophisticated omics platform, which integrates multiple "-omics" technologies such as genomics, proteomics, and transcriptomics. This comprehensive platform enables simultaneous analysis of various biological molecules at an unprecedented scale and resolution. Researchers and scientists can utilize this platform to unravel intricate biological networks, identify biomarkers, and uncover novel therapeutic targets. The omics platform provides a holistic view of cellular and molecular interactions, driving advancements in fields like personalized medicine, drug development, and biomarker discovery. 2. High-Throughput Sequencing: The company offers cutting-edge high-throughput sequencing technologies that empower researchers to rapidly sequence and analyze large volumes of genetic material. This capability is crucial for understanding genetic variations, identifying disease-associated mutations, and studying the dynamic behavior of genes. Nautilus' high-throughput sequencing solutions contribute to accelerating genomics research, paving the way for breakthroughs in genetics, evolutionary biology, and precision medicine. 3. Data Analysis and Interpretation: Nautilus Biotechnology provides advanced bioinformatics and data analysis tools that help researchers derive meaningful insights from complex biological datasets. The company's expertise lies in developing algorithms and software to process and interpret massive amounts of omics data. By offering user-friendly interfaces and powerful analytical capabilities, Nautilus enables scientists to extract valuable information from intricate biological datasets, ultimately enhancing research productivity and driving data-driven decision-making. 4. Collaborative Research Services: In addition to its technology offerings, Nautilus Biotechnology collaborates with research institutions, academic partners, and pharmaceutical companies to jointly address complex scientific challenges. The company's team of skilled experts provides consulting, experimental design, and research support to help clients optimize their studies and leverage Nautilus' technologies effectively. Collaborative research initiatives foster cross-disciplinary innovation and facilitate the translation of scientific discoveries into tangible applications. 5. Industry Partnerships: Nautilus Biotechnology actively seeks partnerships and collaborations with industry leaders, academic institutions, and healthcare organizations. These collaborations aim to combine Nautilus' technological expertise with diverse perspectives and resources, accelerating the development of novel solutions for healthcare, agriculture, environmental sciences, and more.
Financials
Revenue & Profit
Valuation
Ratios
People
Deals
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
Funding
Keywords
Keywords
Classified
Private